Welcome to our dedicated page for Mesoblast SEC filings (Ticker: MEOBF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mesoblast Limited (MEOBF) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer incorporated in Australia. Mesoblast Limited files annual reports under cover of Form 20-F and furnishes current information on Form 6-K pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Mesoblast’s Form 6-K submissions typically attach documents first filed with the Australian Securities Exchange (ASX). These include new issue announcements, notifications of issue, conversion or payment up of unquoted equity securities (Appendix 3G), applications for quotation of securities (Appendix 2A), notifications of cessation of securities (Appendix 3H), proposed issues of securities (Appendix 3B), and change of director’s interest notices (Appendix 3Y), as well as press and news release announcements.
Through this page, users can review how Mesoblast Limited reports on equity securities activity, including issuances, proposed issues, cessations, and applications for quotation, and how it discloses changes in directors’ holdings in its securities. These filings are relevant for investors tracking capital structure developments, director share transactions, and formal corporate announcements.
Stock Titan enhances these filings with AI-powered tools that help explain the structure and contents of lengthy documents. While the original Form 20-F and 6-K texts remain the authoritative sources, AI summaries can highlight key sections, such as equity changes or director interest updates, and make it easier to navigate the exhibits attached from the ASX. Real-time updates from EDGAR ensure that new Mesoblast Limited filings appear promptly, giving users a structured way to follow the company’s regulatory history.
Mesoblast Limited reports early real-world experience and commercial rollout of its FDA-approved cell therapy Ryoncil for children with steroid‑refractory acute graft‑versus‑host disease. Among the first 25 patients treated after launch, 21 were alive after completing the 28‑day course, an 84% survival rate. Access efforts include a MyMesoblast patient hub, onboarding of 45 U.S. transplant centers toward a target of 64 centers covering 94% of transplants, and payer coverage reaching more than 260 million U.S. lives. Mesoblast plans a pivotal adult SR‑aGvHD trial with the NIH‑funded BMT‑CTN expected to begin site enrollment this quarter and is also developing its stromal cell platform for additional inflammatory and cardiovascular indications.
Mesoblast Limited reports that the U.S. FDA has provided feedback supporting a potential Biologics License Application for its allogeneic cell therapy rexlemestrocel-L in chronic discogenic low back pain. After reviewing data from Mesoblast’s first randomized controlled Phase 3 trial, the FDA acknowledged that pain intensity outcomes appear to favor rexlemestrocel-L over placebo, and confirmed that a clinically meaningful reduction in pain at 12 months can support product efficacy. The agency also indicated that robust results on opioid reduction from at least one adequate and well controlled trial could be reflected in the Clinical Studies section of product labeling, meaning the approval label may include opioid reduction. A second 300-patient randomized, placebo-controlled Phase 3 confirmatory trial is over 50% enrolled across about 40 U.S. sites, with enrollment expected to complete in the coming three months.
Mesoblast Limited submitted a Form 6-K as a foreign private issuer, primarily to furnish investors with copies of two equity-related announcements it filed with the Australian Securities Exchange on January 15, 2026. One attached exhibit is an Appendix 3H covering a cessation of securities, and the other is an Appendix 3G relating to the issue, conversion or payment up of unquoted equity securities. These ASX appendices are included as Exhibits 99.1 and 99.2 so U.S. investors can access the same equity capital changes information filed in Australia.
Mesoblast Limited has filed a prospectus covering up to 5,000,000 ordinary shares, represented by 500,000 American Depositary Shares (ADSs), for resale by existing warrant holders. These shares are issuable upon exercise of warrants that carry an exercise price of US$16.25 per ADS.
The warrants, issued in December 2025 as part of a commitment fee tied to subscription agreements for up to US$50 million of subordinated unsecured convertible notes, have a four-year term. Two million warrants are immediately exercisable, while three million become exercisable only if Mesoblast elects to issue the convertible notes. Mesoblast will not receive proceeds from any resale of ADSs by the selling shareholders, but will receive cash upon any warrant exercises.
After this offering, Mesoblast states that 1,290,802,187 ordinary shares will be outstanding, including those underlying the ADSs offered by the shareholders. The company highlights that investing in its ADSs involves a high degree of risk and directs investors to detailed risk factors incorporated by reference.
Mesoblast Limited, an Australia-based biotechnology company, submitted a report outlining several equity-related actions first lodged with the Australian Securities Exchange on January 13, 2026. The company attached three ASX appendices to this report for investors’ reference.
One appendix covers a new issue announcement and notification of issue, conversion or payment up of unquoted equity securities (Appendix 3G). A second appendix details a new issue announcement and application for quotation of securities (Appendix 2A). A third appendix reports a new issue announcement and change of a director’s interest (Appendix 3Y). Together, these documents describe recent equity issuances and an update to director holdings, with the full details contained in the attached exhibits.
Mesoblast Limited, an Australia-incorporated company, submitted a Form 6-K as a foreign private issuer for January 2026. On January 12, 2026, the company filed a new issue announcement and a change of director’s interest notice (Appendix 3Y) with the Australian Securities Exchange, and attached this Appendix 3Y as Exhibit 99.1 to the Form 6-K. The filing indicates Mesoblast reports under Form 20-F and is signed on behalf of the company by its Company Secretary, Niva Sivakumar.
Mesoblast Limited submitted a Form 6-K as a foreign private issuer for January 2026. The company reports that on January 9, 2026 it filed a news release announcement with the Australian Securities Exchange, which is included with this submission as Exhibit 99.1 and incorporated by reference. This filing mainly serves to make that Australian disclosure available to U.S. investors.
Mesoblast Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with information also lodged on the Australian Securities Exchange.
On January 6, 2026, the company filed in Australia a new issue announcement and notification of cessation of securities (Appendix 3H) and a new issue announcement and change of director’s interest notice (Appendix 3Y). These ASX documents are attached to the Form 6-K as Exhibits 99.1 and 99.2 and are incorporated by reference.
Mesoblast Limited submitted a Form 6-K as a foreign private issuer for January 2026. The company reports that on January 2, 2026, it filed a news release announcement with the Australian Securities Exchange, which is attached to this report as Exhibit 99.1 and incorporated by reference.
The filing is signed on behalf of Mesoblast by Company Secretary Paul Hughes and primarily serves to make the same press release available to U.S. investors through the SEC system.